Head and Neck Cancer Clinical Trials

101 studies are recruiting for head and neck cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

   RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patie…

   Stage

   Not phased

   Ages

   21 to 90

   Site

   University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT00900419 on ClinicalTrials.gov

2. Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

   Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to othe…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07667400 on ClinicalTrials.gov

3. SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

   This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or metastatic solid tumors. Phase 1 will identify the recommended dose t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Full-Life Technologies Investigational Site, Minneapolis, Minnesota

   Locations

   2 in total

   Run by

   Full-Life Technologies UK Limited

   See if you can join NCT07873450 on ClinicalTrials.gov

4. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   VA Greater Los Angeles Healthcare System, Los Angeles, California

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

5. Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

   This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R/M HNSCC, delivered with ultrasound-induced microbubble cavitation, with the goal of optimizing delivery of Pembrolizumab and tumor response to Pembrolizumab. Patients will undergo 3 infusions of Pembrolizum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07501650 on ClinicalTrials.gov

6. Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

   Finding effective ways to slow down or prevent the development of cancer in people with Fanconi anemia (FA) is a critical medical priority. Individuals with FA are at dramatically higher risk of developing aggressive cancers, particularly of the head and neck, and these cancers are difficult to tre…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of MInnesota, Minneapolis, Minnesota

   Locations

   2 in total

   Run by

   Rockefeller University

   See if you can join NCT07901959 on ClinicalTrials.gov

7. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

8. A Motion Exergaming Approach for Symptom Management: HNC

   This overall objective of the RCT is to test an intervention to overcome the PA barriers for head and neck cancer (HNC) patients during the first 6 months after their treatment. PAfitME stands for a personalized Physical Activity intervention with fitness graded Motion Exergames. PAfitME is deliver…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04632654 on ClinicalTrials.gov

9. PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

   The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06239220 on ClinicalTrials.gov

10. PDT For Induction Therapy For Head And Neck Cancer

    This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT07214987 on ClinicalTrials.gov

11. Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

    Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UMPC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Matthew Spector

    See if you can join NCT07631650 on ClinicalTrials.gov

12. Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

    The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during surgery in adults with head and neck squamous cell carcinoma (HNSCC) who…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT07741643 on ClinicalTrials.gov

13. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

14. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

    A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 105 - START Los Angeles, Los Angeles, California

    Locations

    8 in total

    Run by

    EpiBiologics

    See if you can join NCT07462377 on ClinicalTrials.gov

15. Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

    This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread …

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    University of Kentucky Markey Cancer Center, Lexington, Kentucky

    Run by

    Mark Bernard

    See if you can join NCT07770100 on ClinicalTrials.gov

16. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    31 in total

    Run by

    Pfizer

    See if you can join NCT07090499 on ClinicalTrials.gov

17. Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia

    Radiation-induced xerostomia (dry mouth) is one of the most common and severe side effects for patients receiving radiation therapy for head and neck cancer. New approaches are needed to reduce this side effect and improve patients' quality of life after treatment. This is a Phase II, single-center…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07278557 on ClinicalTrials.gov

18. A Study of a New PET Scanner in People With Cancer

    The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07690917 on ClinicalTrials.gov

19. Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body

    This trial studies how well dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) works in diagnosing osteoradionecrosis in patients with head and neck cancer that is primary, has come back, or has spread to other places in the body who are undergoing radiation therapy. DCE-MRI may help do…

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT03145077 on ClinicalTrials.gov

20. Preventing Lymphedema in Patients Undergoing Surgical Treatment for Head and Neck Cancer Through Vein Reconstruction

    * The goal of this clinical trial is to learn if facial vein reconstruction after neck dissection works to reduce rates of lymphedema in adults getting surgical treatment for head and neck cancer. This is a trial which aims to improve the rate of lymphedema for patients undergoing treatment for hea…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UPMC Presbyterian Hospital and UPMC Shadyside Hospital, Pittsburgh, Pennsylvania

    Run by

    University of Pittsburgh

    See if you can join NCT07694726 on ClinicalTrials.gov

21. Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

    To find the recommended dose of an investigational therapy called chimeric antigen receptor (CAR).TROP2/interleukin (IL)15-transduced TGFBR2 KO cord blood (CB)-derived natural killer (NK) cells (TROP2 CAR/IL-15 TGFBR2 KO NK cells) that can be given with and without preconditioning radiation therapy…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07101432 on ClinicalTrials.gov

22. Using Silverlon® for Head and Neck Patients With Tracheostomies

    The purpose of this study is to determine if prophylactic silver-nylon burn dressing Silverlon® prevents a severe skin reaction under tracheostomy collars. It also aims to establish whether patients can tolerate Silverlon® under their tracheostomy with daily removal and weekly changes.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Upstate Medical University, Syracuse, New York

    Run by

    State University of New York - Upstate Medical University

    See if you can join NCT07856732 on ClinicalTrials.gov

23. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    University of San Diego Moores Cancer Center, La Jolla, California

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

24. Distance-Based Exercise to Preserve Function and Prevent Disability

    This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Kaiser Permanente Dublin, Dublin, California

    Locations

    23 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT07059884 on ClinicalTrials.gov

25. Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

    This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06997068 on ClinicalTrials.gov